000			03083cam a2200361 a 4500
003			EG-GiCUC
005			20250223032918.0
008			220208s2021 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.19.06.Ph.D.2021.Mo.I
100	0		_aMohamed Mahmoud Amin
245	1	0	_aIMRT with or without concomitant chemotherapy for patients with unresectable pleural mesothelioma after neoadjuvant chemotherapy / _cMohamed Mahmoud Amin ; Supervised Mohamed Moustafa Lotayef , Rabab Mohamed Gaafar , Abdelrahman Mohamed Abdelrahman
246	1	5	_aالعلاج الأشعاعى معدل الكثافة مع او بدون العلاج الكيميائى لمرضى أورام الغشاء البلورى للرئة الغير مستأصله جراحياً
260			_aCairo : _bMohamed Mahmoud Amin , _c2021
300			_a132 P . : _bcharts , facsmilies ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology Radiation
520			_aThis is prospective study-reviewing patients with pleural mesothelioma who are unable to undergo surgery. We have implemented a technique using intensity-modulated radiotherapy (IMRT) to treat these patients. This work aimed to study the toxicity and effect of radiotherapy on progression-free survival and overall survival. {uF076} Patients and methods: Between 2016 and 2020, 50 patients with unresectable malignant pleural mesothelioma following chemotherapy, of both sex and different age groups, were treated with pleural IMRT to the hemithorax (median dose, 46.8 Gy) with or without concurrent chemotherapy at The National Cancer Institute, Cairo University. {uF076} Results: Of the 50 patients, 38% had stage II, 62 % had stage III, and all received induction chemotherapy (mostly cisplatin and pemetrexed) before IMRT. Of the 50 patients, thirty-nine patients (78%) were able to complete the radiotherapy protocol. Twenty-seven patients (69.2%) experienced Grade II pneumonitis while twelve patients of the thirty-nine patients (30.8%) experienced grade-III or higher pneumonitis. The median survival for all the patients in the study was 20.5 months. The 1-year and 2-years OS were 84.7 % and 31.4 %, respectively, with no significant difference in overall survival between the two arms. Patients who received two lines of chemotherapy had statistically significant better overall survival than patients who received one line of chemotherapy with a median survival of 32 months compared to 16.2 months respectively.(P=0.001)
530			_aIssued also as CD
650		0	_aPneumonities
653		4	_aMalignant pleural mesothelioma
653		4	_aPneumonitis
653		4	_aRadiotherapy
700	0		_aAbdelrahman Mohamed Abdelrahman , _eSupervising
700	0		_aMohamed Moustafa Lotayef , _eSupervising
700	0		_aRabab Mohamed Gaafar, _eSupervising
856			_uhttp://172.23.153.220/th.pdf
905			_aAmira _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c84155 _d84155